{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-011005","form_type":"8-K","ticker":"LXEO","cik":"0001907108","company_name":"Lexeo Therapeutics, Inc.","filed_at":"2024-02-05T23:59:59+00:00","discovered_at":"2026-05-14T18:03:26.288999+00:00","generated_at":"2026-06-06T09:25:02.939545+00:00","sec_items":["7.01","9.01"],"event_type":"leadership","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Lexeo appoints CDO, CMO, Senior Advisor, and Chief Business & Legal Officer","bullets":["Sandi See Tai promoted to Chief Development Officer; previously VP at Pfizer, led tafamidis ATTR-ACT program.","Eric Adler appointed Chief Medical Officer & Head of Research; former CSO at Lexeo, UCSD professor, gene therapy pioneer.","Rajiv Patni named Senior Advisor to CEO & Board; former CRO at Reata (acquired by Biogen), led Skyclarys approval.","Jenny Robertson promoted to Chief Business and Legal Officer; previously Chief Legal & Admin Officer, Pfizer rare disease counsel."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-011005","json":"https://secwatch.observer/filing/0000950170-24-011005.json","markdown":"https://secwatch.observer/filing/0000950170-24-011005.md","text":"https://secwatch.observer/filing/0000950170-24-011005.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1907108/000095017024011005/0000950170-24-011005-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1907108/000095017024011005/lxeo-20240205.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-06T09:25:02.939545+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}